# Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

> **NCT04202679** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 160 (actual)

## Conditions studied

- Neurodermatitis

## Interventions

- **DRUG:** Dupilumab SAR231893
- **DRUG:** Placebo
- **DRUG:** Moisturizers
- **DRUG:** Low to medium potent topical corticosteroids
- **DRUG:** Topical calcineurin inhibitors

## Key facts

- **NCT ID:** NCT04202679
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-16
- **Primary completion:** 2021-08-30
- **Final completion:** 2021-11-22
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2025-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04202679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04202679, "Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04202679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*